Background: Education and self-management awareness are established components of multidisciplinary (MDT) care for IJD. The format and delivery of such a programme varies according to local circumstance. There is little evidence to support any specific model of delivery. Previously in this unit, patients attended a two hour session held at three monthly intervals. Members of the MDT addressed aspects of IJD management, such as clarification of team and patient roles, symptoms, and self-management strategies including activity modifications and joint protection. Consultation with patient groups revealed this format, delivery and content was too rigid and inhibited full engagement. The programme was therefore re-designed to improve patient involvement from just participation to full engagement. Methods: From August 2012, a modified weekly group education and exercise programme of 90 minute sessions has been provided for up to 8 participants led by two rheumatology physiotherapists experienced in delivering self-management and coping strategies for IJD. New patients, established cases with disease flares and annual reviews were included. Thus frequency of attendance at the sessions varied, depending on patient circumstance and therapist's perception of need for knowledge and support. The sessions always included an educational review followed by basic stretching and strengthening exercises, with emphasis on specific areas such as posture, hands and feet, relevant to the individual. Participants were also invited to suggest topics for discussion or further explanation and a record of this was kept. A patient experience questionnaire was completed. Results: In 12 months from August 2012, 78 patients with IJD were enrolled; 10 patients failed to attend. There were 285 attendances out of a possible total 392 (73%) with an average of 5.8 patients per session. The mean attendance per patient was 4.4. In all, 47 patients (69%) completed the questionnaire which reviewed the programme in 10 domains each scored on a 10-point satisfaction scale clustered into two sets of 5 domains covering patient experience and educational merit. Mean patient experience and educational merit scores were 9.004 and 8.881 respectively and ranged from 8.553 to 9.298. Conclusion: This audit of a new physiotherapy programme for IJD assessed patient experience and educational merit. There was 100% participation in the new programme (scores of 5-10) with 72% of patients reporting complete satisfaction and engagement in it (scores of 9 & 10).
The new programme scored highest for its patient-friendly, flexible structure and practical training sessions. It is central to the continued delivery of high quality care for IJD and provides a platform for further development of both the MDT care package and the formalized assessment of disease outcome. Disclosure statement: The authors have declared no conflicts of interest. Department of Rheumatology, Cannock Chase Hospital, Cannock, UK Background: The advent of biologics has revolutionized the management of RA, making disease remission an achievable goal. Certolizumab pegol, a pegylated TNF inhibitor was approved by NICE for treatment of RA patients in February 2010 with the initial 3 months provided free of charge. We share our experience at Cannock with certolizumab pegol for RA patients in routine clinical practice over the last 2 years. Methods: It is an observational study with retrospective review of records of all RA patients who commenced certolizumab pegol between June 2010 and Aug 2012. Data collected included age, gender, number of previous DMARDs, previous biologic use, disease activity score (DAS 28) at baseline, 3 months, 6 months, 12 months and 18 months and outcome of treatment including side effects. Results: In about 2 years, 152 RA patients have been treated with certolizumab pegol at Cannock. The mean age of the patients was 57.1 years (AE13.2) and the majority (67.3%) were female. The average number of previous DMARDs was 2.3 and the mean baseline DAS28 was 6.2 AE 0.6.
AUDIT OF OSTEOPOROTIC HIP FRACTURES AND COMPLIANCE WITH ANTI-RESORPTIVE MEDICATIONS
The majority of patients were TNFi naïve, but 28% of them had switched from a previous biologic agent. The average improvement in DAS28 at 3, 6, 12 and 18 months was 2.9 AE 1.7, 2.5 AE 1.9, 2.8AE1.8 and 2.7 AE 1.6, respectively. Of the 108 TNFi naïve patients on certolizumab pegol with complete outcome measures at 6 months, 80% had responded with a DAS28 improvement ! 1.2 at 3 months. 77% of the patients persisted with the drug, but 23% discontinued it due to either primary inefficacy (11%), secondary inefficacy (6%) or intolerance (6%). Injection site reactions only occurred in one patient. No serious infections were seen apart from one case of tuberculosis that occurred 4 weeks after stopping certolizumab pegol. Of the 44 patients who previously had biologics, 14 (31%) discontinued the drug due to inefficacy (primary inefficacy n ¼ 11, secondary inefficacy n ¼ 3). Conclusion: In our experience over 2 years reflecting real life practice, certolizumab pegol is safe, well tolerated and has a similar efficacy to other TNFi in RA patients. It has also resulted in a considerable savings to the local health economy (approx. 500k). 
